Possible role of the JAK/STAT pathways in the regulation of T cell-interferon related genes in systemic lupus erythematosus

Lupus

Volumn 20, Issue 12, 2011, Pages 1231-1239

  Kawasaki, M ^a   Fujishiro, M ^a   Yamaguchi, A ^a,b   Nozawa, K ^a   Kaneko, H ^c   Takasaki, Y ^b   Takamori, K ^a   Ogawa, H ^a   Sekigawa, I ^a  

^a JUNTENDO UNIVERSITY   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c 1 7 1 Kohnodai   (Japan)

Author keywords

Interferon (IFN); Janus kinase (JAK); Signal transducer and activator of transcription (STAT); Systemic lupus erythematosus (SLE)

Indexed keywords

CARDIOLIPIN ANTIBODY; DNA ANTIBODY; INTERFERON; INTERFERON REGULATORY FACTOR; JANUS KINASE; JANUS KINASE INHIBITOR; PREDNISOLONE; PROTEIN INHIBITOR; RIBONUCLEOPROTEIN ANTIBODY; RO ANTIBODY; SM ANTIBODY; STAT PROTEIN;

ADULT; AGED; ARTHRITIS; ARTICLE; CD3+ T LYMPHOCYTE; CLINICAL ARTICLE; DISEASE ACTIVITY; DNA MICROARRAY; DRUG TARGETING; FEMALE; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PLEURISY; PRIORITY JOURNAL; PROTEINURIA; RASH; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA;

ADULT; AGED; BASE SEQUENCE; DNA PRIMERS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INTERFERON REGULATORY FACTORS; JANUS KINASES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS; T-LYMPHOCYTES; YOUNG ADULT;

EID: 80053623446     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203311409963     Document Type: Article

References (33)

1. Sekigawa I, Naito T, Hira K, et al. Possible mechanisms of gender bias in SLE: new hypothesis involving a comparison of SLE with atopy. Lupus. 2004 ; 13: 217-222 (Pubitemid 38649619)
2. Sekigawa I, Kawasaki M, Ogasawara H, et al. DNA methylation: its contribution to systemic lupus erythematosus. Clin Exp Med. 2006 ; 6: 99-106 (Pubitemid 44630739)
3. Kawasaki M, Kaneda K, Kaneko H, Sekigawa I, Takasaki Y, Ogawa H. Two cases of dermatomyositis associated with interstitial pneumonia: comprehensive study of gene expression. Clin Exp Rheumatol. 2008 ; 26: 79-380
4. Kawasaki M, Sekigawa I, Nozawa K, et al. Changes in the gene expression of peripheral blood mononuclear cells during the menstrual cycle of females is associated with a gender bias in the incidence of systemic lupus erythematosus. Clin Exp Rheumatol. 2009 ; 27: 260-266
5. Kawasaki M, Fujishiro M, Yamaguchi A, et al. Fluctuations in the gene expression of peripheral blood mononuclear cells between the active and inactive phases of systemic lupus erythematosus. Clin Exp Rheumatol. 2010 ; 28: 311-317
6. Qing X, Putterman C. Gene expression profiling in the study of the pathogenesis of systemic lupus erythematosus. Autoimmun Rev. 2004 ; 3: 505-509 (Pubitemid 39531242)
7. Gladkevich A, Nelemans A, Kauffman HF, Korf J. Microarray profiling of lymphocytes in internal diseases with an altered immune response : potential and methodology. Mediators Inflamm. 2005 ; 6: 317-330 (Pubitemid 41803400)
8. Dai Y, Huang YS, Tang M, et al. Microarray analysis of microRNA expression in peripheral blood cells of systemic lupus erythematosus patients. Lupus. 2007 ; 16: 939-946
9. Nakou M, Knowlton N, Frank MB, et al. Gene expression in systemic lupus erythematosus: bone marrow analysis differentiates active from inactive disease and reveals apoptosis and granulopoiesis signatures. Arthritis Rheum. 2008 ; 58: 3541-3549
10. Nikpour M, Dempsey AA, Urowitz MB, Gladman DD, Barnes DA. Association of a gene expression profile from whole blood with disease activity in systemic lupus erythematosus. Ann Rheum Dis. 2008 ; 67: 1069-1075
11. Lee HM, Mima T, Sugino H, et al. Interactions among type I and type II interferon, tumor necrosis factor, and beta-estradiol in the regulation of immune response-related gene expressions in systemic lupus erythematosus. Arthritis Res Ther. 2009 ; 11: R1 - R1
12. Li QZ, Zhou J, Lian Y, et al. Interferon signature gene expression is correlated with autoantibody profiles in patients with incomplete lupus syndromes. Clin Exp Immunol. 2010 ; 159: 281-291
13. Tan EN, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 ; 25: 1271-1277 (Pubitemid 13221242)
14. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992 ; 35: 630-640
15. Haas C, Ryffel B, Le Hir M. IFN-gamma is essential for the development of autoimmune glomerulonephritis in MRL/lpr mice. J Immunol. 1997 ; 158: 5484-5491 (Pubitemid 127681257)
16. Nicoletti F, Di Marco R, Zaccone P, et al. Dichotomic effects of IFN-gamma on the development of systemic lupus erythematosus like syndrome in MRL-lpr/lpr mice. Eur J Immunol. 2000 ; 30: 438-447 (Pubitemid 30098836)
17. Ioannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum. 2000 ; 43: 1431-1442 (Pubitemid 30452458)
18. Min DJ, Cho ML, Cho CS, et al. Decreased production of interleukin-12 and interferon-gamma is associated with renal involvement in systemic lupus erythematosus. Scand J Rheumatol. 2001 ; 30: 159-163
19. Dall'era MC, Cardarelli PM, Preston BT, Witte A, Davis Jr JC. Type I interferon correlates with serological and clinical manifestations of SLE. Ann Rheum Dis. 2005 ; 64: 1692-1697 (Pubitemid 41667141)
20. Reilly CM, Olgun S, Goodwin D, et al. Interferon regulatory factor-1 gene deletion decreases glomerulonephritis in MRL/lpr mice. Eur J Immunol. 2006 ; 36: 1296-1308
21. Qing Y, Stark GR. Alternative activation of STAT1 and STAT3 in response to interferon-gamma. J Biol Chem. 2004 ; 279: 41,679-41,685
22. De Prati AC, Ciampa AR, Cavalieri E, et al. STAT1 as a new molecular target of anti-inflammatory treatment. Curr Med Chem. 2005 ; 12: 1819-1828 (Pubitemid 41015180)
23. Dong J, Wang QX, Zhou CY, Ma XF, Zhang Y. Activation of the STAT1 signaling pathway in lupus erythematosus in MRL/lpr mice. Lupus. 2007 ; 16: 101-109 (Pubitemid 46347932)
24. Denuc A, Marfany G. SUMO and ubiquitin paths converge. Biochem Soc Trans. 2010 ; 38: 34-39
25. Strandberg L, Ambrosi A, Espinosa A, et al. Interferon-alpha induces up-regulation and nuclear translocation of the Ro52 autoantigen as detected by a panel of novel Ro52-specific monoclonal antibodies. J Clin Immunol. 2008 ; 28: 220-231
26. Meinecke I, Pap G, Mendoza H, et al. The small ubiquitin-like modifier mediates the resistance of prosthesis-loosening fibroblast-like synoviocytes against fas-induced apoptosis. Arthritis Rheum. 2009 ; 60: 2065-2070
27. Kawagoe T, Takeuchi O, Takabatake Y, et al. TANK is a negative regulator of Toll-like receptor signaling and is critical for the prevention of autoimmune nephritis. Nat Immunol. 2009 ; 10: 965-972
28. Epinosa A, Zhou W, Ek M, et al. The Sjogren,s syndrome-associated autoantigen Ro52 is an E3 ligase that regulates proliferation and cell death. J Immunol. 2006 ; 176: 6277-6285
29. Wada K, Kamitani T. Autoantigen Ro52 is an E3 ubiquitin ligase. Biochem Biophys Res Commun. 2006 ; 339: 415-421 (Pubitemid 41697564)
30. Sabile A, Meyer AM, Wirbelauer C, et al. Regulation of p27 degradation and S-phase progression by Ro52 RING finger protein. Mol Cell Biol. 2006 ; 26: 5994-6004 (Pubitemid 44204519)
31. Kasperkovitz PV, Verbeer NL, Smeets TJ, et al. Activation of the STAT1 pathway in rheumatoid arthritis. Ann Rheum Dis. 2004 ; 63: 233-239 (Pubitemid 38250663)
32. Coombs JH, Bloom BJ, Breedveld FC, et al. Improved pain, physical functional and health status in patients with rheumatoid arthritis treated with CP-690.550. an oral active janus kinase (JAK) inhibitor: Results from a randomized, double-blind, placebo-controlled trial. Ann Rheum Dis. 2010 ; 69: 413-416
33. Quintas-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010 ;: